Skip to main content
SpringerLink
Log in
Book cover

Cutaneous Melanoma pp 827–850Cite as

Isolated Limb Infusion for Melanoma

  • Reference work entry
  • First Online:

Abstract

Isolated limb infusion (ILI) using melphalan and dactinomycin (actinomycin D) was developed as a simplified and minimally invasive alternative to the traditional, more invasive, and elaborative isolated limb perfusion (ILP) to treat unresectable metastatic melanoma confined to the limb. An increasing number of centers around the world have reported their results using the procedure. Reports from different centers have shown that the procedure is safe, with mild-to-moderate regional toxicity, and results in satisfactory response rates. When comparing ILI and ILP, it must be borne in mind that ILI is often performed in significantly older patients and in patients with higher stages of disease, which decreases the likelihood of a favorable response. Even in this era of effective systemic therapies for metastatic melanoma, ILI is still worthwhile and a relatively straightforward, single-treatment option to treat locally recurrent or in-transit metastatic melanoma involving a limb. Due to its minimally invasive nature, ILI is an ideal platform to test new drugs and drug combinations. Potential exists to further improve ILI response rates when combined with novel therapies.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   599.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD   899.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

References

  • Aloia TA, Grubbs E, Onaitis M et al (2005) Predictors of outcome after hyperthermic isolated limb perfusion: role of tumor response. Arch Surg 140:1115–1120

    Article  PubMed  Google Scholar 

  • Andtbacka RH, Kaufman HL, Collichio F et al (2015) Talimogene laherparepvec improves durable response rate in patients with advanced melanoma. J Clin Oncol 33:2780–2788

    Article  CAS  PubMed  Google Scholar 

  • Ariyan CE, Brady MS, Siegelbaum RH et al (2018) Robust antitumor responses result from local chemotherapy and CTLA-4 blockade. Cancer Immunol Res 6: 189–200

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Beasley GM, Petersen RP, Yoo J et al (2008) Isolated limb infusion for in-transit malignant melanoma of the extremity: a well-tolerated but less effective alternative to hyperthermic isolated limb perfusion. Ann Surg Oncol 15:2195–2205

    Article  PubMed  Google Scholar 

  • Beasley GM, Caudle A, Petersen RP et al (2009) A multi-institutional experience of isolated limb infusion: defining response and toxicity in the US. J Am Coll Surg 208:706–715

    Article  PubMed  Google Scholar 

  • Beasley GM, Riboh JC, Augustine CK et al (2011a) Prospective multicenter phase II trial of systemic ADH-1 in combination with melphalan via isolated limb infusion in patients with advanced extremity melanoma. J Clin Oncol 29:1210–1215

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Beasley GM, Coleman AP, Raymond A et al (2011b) A phase I multi-institutional study of systemic sorafenib in conjunction with regional melphalan for in-transit melanoma of the extremity. Ann Surg Oncol 19: 3896–3905

    Article  Google Scholar 

  • Beasley GM, Sharma K, Wong J et al (2012) A multi-institution experience comparing the clinical and physiologic differences between upper extremity and lower extremity melphalan-based isolated limb infusion. Cancer 118:6136–6143

    Article  CAS  PubMed  Google Scholar 

  • Beasley GM, Speicher P, Augustine CK et al (2015) A multicenter phase I dose escalation trial to evaluate safety and tolerability of intra-arterial temozolomide for patients with advanced extremity melanoma using normothermic isolated limb infusion. Ann Surg Oncol 22:287–294

    Article  PubMed  Google Scholar 

  • Bland KI, Kimura AK, Brenner DE et al (1989) A phase II study of the efficacy of diamminedichloroplatinum (cisplatin) for the control of locally recurrent and in-transit malignant melanoma of the extremities using tourniquet outflow-occlusion techniques. Ann Surg 209:73–80

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Bonenkamp JJ, Thompson JF, de Wilt JH et al (2004) Isolated limb infusion with fotemustine after dacarbazine chemosensitisation for inoperable loco-regional melanoma recurrence. Eur J Surg Oncol 30:1107–1112

    Article  CAS  PubMed  Google Scholar 

  • Brady MS, Brown K, Patel A et al (2006) A phase II trial of isolated limb infusion with melphalan and dactinomycin for regional melanoma and soft tissue sarcoma of the extremity. Ann Surg Oncol 13:1123–1129

    Article  PubMed  Google Scholar 

  • Brady MS, Brown K, Patel A et al (2009) Isolated limb infusion with melphalan and dactinomycin for regional melanoma and soft-tissue sarcoma of the extremity: final report of a phase II clinical trial. Melanoma Res 19:106–111

    Article  PubMed  Google Scholar 

  • Brown MC, Holl EK, Boczkowski D et al (2017) Cancer immunotherapy with recombinant poliovirus induces IFN-dominant activation of dendritic cells and tumor antigen-specific CTLs. Sci Transl Med 9(408). http://stm.sciencemag.org/content/9/408/eaan4220.short

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  • Callahan MK, Kluger H, Postow MA et al (2018) Nivolumab plus ipilimumab in patients with advanced melanoma: updated survival, response, and safety data in a phase I dose-escalation study. J Clin Oncol 36:391–398

    Article  CAS  PubMed  Google Scholar 

  • Cassumbhoy R, Pitman AG (2007) Isolated limb infusion for local control of lower limb melanoma: radiologic aspects. Australas Radiol 51:543–549

    Article  CAS  PubMed  Google Scholar 

  • Cavaliere R, Ciocatto EC, Giovanella BC et al (1967) Selective heat sensitivity of cancer cells. Biochemical and clinical studies. Cancer 20:1351–1381

    Article  CAS  PubMed  Google Scholar 

  • Chai CY, Deneve JL, Beasley GM et al (2012) A multi-institutional experience of repeat regional chemotherapy for recurrent melanoma of extremities. Ann Surg Oncol 19:1637–1643

    Article  PubMed  Google Scholar 

  • Chang SY, Alberts DS, Farquhar D et al (1978) Hydrolysis and protein binding of melphalan. J Pharm Sci 67: 682–684

    Article  CAS  PubMed  Google Scholar 

  • Chapman PB, Hauschild A, Robert C et al (2011) Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 364: 2507–2516

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Cheng TY, Grubbs E, Abdul-Wahab O et al (2003) Marked variability of melphalan plasma drug levels during regional hyperthermic isolated limb perfusion. Am J Surg 186:460–467

    Article  CAS  PubMed  Google Scholar 

  • Clark J, Grabs AJ, Parsons PG et al (1994) Melphalan uptake, hyperthermic synergism and drug resistance in a human cell culture model for the isolated limb perfusion of melanoma. Melanoma Res 4:365–370

    Article  CAS  PubMed  Google Scholar 

  • Common Terminology Criteria for Adverse Events v3.0 (CTCAE) (2006) https://ctep.cancer.gov/protocolDevelopment/electronic_applications/docs/ctcaev3.pdf. Accessed 22 Aug 2018

  • Cornett WR, McCall LM, Petersen RP et al (2006) Randomized multicenter trial of hyperthermic isolated limb perfusion with melphalan alone compared with melphalan plus tumor necrosis factor: American College of Surgeons Oncology Group Trial Z0020. J Clin Oncol 24:4196–4201

    Article  CAS  PubMed  Google Scholar 

  • Coventry BJ, Kroon HM, Giles MH et al (2014) Australian multi-center experience outside of the Sydney Melanoma Unit of isolated limb infusion chemotherapy for melanoma. J Surg Oncol 109:780–785

    Article  CAS  PubMed  Google Scholar 

  • Damian DL, Barnetson RS, Rose BR et al (2001) Treatment of refractory hand warts by isolated limb infusion with melphalan and actinomycin D. Australas J Dermatol 42:106–109

    Article  CAS  PubMed  Google Scholar 

  • Damian DL, Barnetson RS, Thompson JF (2006) Treatment of refractory chromomycosis by isolated limb infusion with melphalan and actinomycin D. J Cutan Med Surg 10:48–51

    Article  PubMed  Google Scholar 

  • Defty CL, Marsden JR (2012) Melphalan in regional chemotherapy for locally recurrent metastatic melanoma. Curr Top Med Chem 12:53–60

    Article  CAS  PubMed  Google Scholar 

  • Dossett LA, Ben-Shabat I, Olofsson Bagge R et al (2016) Clinical response and regional toxicity following isolated limb infusion compared with isolated limb perfusion for in-transit melanoma. Ann Surg Oncol 23:2330–2335

    Article  PubMed  Google Scholar 

  • Duprat Neto JP, Mauro AC, Molina AS et al (2014) Isolated limb infusion with hyperthermia and chemotherapy for advanced limb malignancy: factors influencing toxicity. ANZ J Surg 84:677–682

    Article  PubMed  Google Scholar 

  • Eisenhauer E, Therasse P, Bogaerts J et al (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45: 228–247

    Article  CAS  PubMed  Google Scholar 

  • Elhassadi E, Egan E, O’Sullivan G et al (2006) Isolated limb infusion with cytotoxic agent for treatment of localized refractory cutaneous T-cell lymphoma. Clin Lab Haematol 28:279–281

    Article  CAS  PubMed  Google Scholar 

  • Fletcher WS, Pommier R, Small K (1994) Results of cisplatin hyperthermic isolation perfusion for stage IIIA and IIIAB extremity melanoma. Melanoma Res 4(Suppl 1):17–19

    PubMed  Google Scholar 

  • Franklin C, Livingstone E, Roesch A et al (2017) Immunotherapy in melanoma: recent advances and future directions. Eur J Surg Oncol 43:604–661

    Article  CAS  PubMed  Google Scholar 

  • Gershenwald JE, Scolyer RA, Hess KR et al (2017) Melanoma staging: evidence-based changes in the American Joint Committee on Cancer eighth edition cancer staging manual. CA Cancer J Clin 67:472–492

    Article  PubMed  PubMed Central  Google Scholar 

  • Grob JJ, Amonkar MM, Karaszewska B et al (2015) Comparison of dabrafenib and trametinib combination therapy with vemurafenib monotherapy on health-related quality of life in patients with unresectable or metastatic cutaneous BRAF Val600-mutation-positive melanoma (COMBI-v): results of a phase 3, open-label, randomised trial. Lancet Oncol 16:1389–1398

    Article  CAS  PubMed  Google Scholar 

  • Grünhagen DJ, Kroon HM, Verhoef C (2015) Perfusion and infusion for melanoma in-transit metastases in the era of effective systemic therapy. Am Soc Clin Oncol Educ Book 35:e528–e534

    Article  Google Scholar 

  • Hansson J, Lewensohn R, Ringborg U et al (1987) Formation and removal of DNA cross-links induced by melphalan and nitrogen mustard in relation to drug-induced cytotoxicity in human melanoma cells. Cancer Res 47:2631–2637

    CAS  PubMed  Google Scholar 

  • Hauschild A, Grob JJ, Demidov LV et al (2012) Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet 380:358–365

    Article  CAS  PubMed  Google Scholar 

  • Howie LJ, Tyler DS, Salama AK (2015) Neoadjuvant use of ipilimumab in locally advanced melanoma. J Surg Oncol 112:841–843

    Article  CAS  PubMed  Google Scholar 

  • Huismans AM, Kroon HM, Kam PC et al (2011) Does increased experience with isolated limb infusion for advanced limb melanoma influence outcome? A comparison of two treatment periods at a single institution. Ann Surg Oncol 18:1877–1883

    Article  PubMed  Google Scholar 

  • Huismans AM, Kroon HM, Kam PC et al (2016) Isolated limb infusion. In: Aigner KR, Stephens FO (eds) Regional therapy of malignant tumors, 2nd edn. Springer, Heidelberg/Berlin, pp 375–390

    Google Scholar 

  • Jiang BS, Speicher PJ, Thomas S et al (2015) Quality of life after isolated limb infusion for in-transit melanoma of the extremity. Ann Surg Oncol 22:1694–1700

    Article  PubMed  Google Scholar 

  • Karakousis CP, Kanter PM, Lopez R et al (1979) Modes of regional chemotherapy. J Surg Res 26:134–141

    Article  CAS  PubMed  Google Scholar 

  • Karakousis CP, Kanter DM, Park PC et al (1982) Tourniquet infusion versus hyperthermic perfusion. Cancer 49:850–858

    Article  CAS  PubMed  Google Scholar 

  • Katsarelias D, Rådbo E, Ben-Shabat I et al (2018) The effect of temperature and perfusion time on response, toxicity, and survival in patients with in-transit melanoma metastases treated with isolated limb perfusion. Ann Surg Oncol. https://doi.org/10.1245/s1043401864599

  • Klaase JM, Kroon BBR, Beijnen JH et al (1994) Melphalan tissue concentrations in patients treated with regional isolated perfusion for melanoma of the lower limb. Br J Cancer 70:151–153

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Koops HS, Lejeune KJ, Kroon BBR et al (2004) Isolated limb perfusion for melanoma: technical aspects. In: Thompson JF, Morton DL, Kroon BBR (eds) Textbook of melanoma, 1st edn. Martin Dunitz, London, pp 404–409

    Google Scholar 

  • Kroon BB (1988) Regional isolation perfusion in melanoma of the limbs; accomplishments, unsolved problems, future. Eur J Surg Oncol 14:101–110

    CAS  PubMed  Google Scholar 

  • Kroon HM, Moncrieff M, Kam PC et al (2008) Outcomes following isolated limb infusion for melanoma. A 14-year experience. Ann Surg Oncol 15:3003–3013

    Article  PubMed  Google Scholar 

  • Kroon HM, Lin DY, Kam PC et al (2009a) Efficacy of repeat isolated limb infusion with melphalan and actinomycin D for recurrent melanoma. Cancer 115: 1932–1940

    Article  CAS  PubMed  Google Scholar 

  • Kroon HM, Lin DY, Kam PC et al (2009b) Isolated limb infusion as palliative treatment for advanced limb disease in patients with AJCC stage IV melanoma. Ann Surg Oncol 16:1193–1201

    Article  PubMed  Google Scholar 

  • Kroon HM, Moncrieff M, Kam PC et al (2009c) Factors predictive of acute regional toxicity after isolated limb infusion with melphalan and actinomycin D in melanoma patients. Ann Surg Oncol 16:1184–1192

    Article  PubMed  Google Scholar 

  • Kroon HM, Huismans AM, Kam PC et al (2014a) Isolated limb infusion with melphalan and actinomycin D for melanoma: a systematic review. J Surg Oncol 109:348–351

    Article  CAS  PubMed  Google Scholar 

  • Kroon HM, Huismans A, Waugh RC et al (2014b) Isolated limb infusion: technical aspects. J Surg Oncol 109:352–356

    Article  PubMed  Google Scholar 

  • Kroon HM, Coventry BJ, Giles MH et al (2016) Australian multicentre study of isolated limb infusion for melanoma. Ann Surg Oncol 23:1096–1103

    Article  PubMed  Google Scholar 

  • Kroon HM, Coventry BJ, Giles MH et al (2017) Safety and efficacy of isolated limb infusion chemotherapy for advanced locoregional melanoma in elderly patients: an Australian multicentre study. Ann Surg Oncol 24:3245–3251

    Article  PubMed  Google Scholar 

  • Lidsky ME, Speicher PJ, Jiang B et al (2014) Isolated limb infusion as a model to test new agents to treat metastatic melanoma. J Surg Oncol 109:357–365

    Article  PubMed  Google Scholar 

  • Lindner P, Doubrovsky A, Kam PC et al (2002) Prognostic factors after isolated limb infusion with cytotoxic agents for melanoma. Ann Surg Oncol 9:127–136

    Article  PubMed  Google Scholar 

  • Lindner P, Thompson JF, De Wilt JH et al (2004) Double isolated limb infusion with cytotoxic agents for recurrent and metastatic limb melanoma. Eur J Surg Oncol 30:433–439

    Article  CAS  PubMed  Google Scholar 

  • Long GV, Hauschild A, Santinami M et al (2017) Adjuvant dabrafenib plus trametinib in stage III BRAF-mutated melanoma. N Engl J Med 377:1813–1823

    Article  CAS  PubMed  Google Scholar 

  • Marsden J, Samarasinghe V, Duddy M et al (2008) Regional chemotherapy for inoperable limb cancer using isolated limb infusion. Br J Dermatol 159:10

    Google Scholar 

  • McArthur GA, Chapman PB, Robert C et al (2014) Safety and efficacy of vemurafenib in BRAF(V600E) and BRAF(V600K) mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study. Lancet Oncol 15:323–332

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • McDermott DF, Sosman JA, Gonzalez R et al (2008) Double-blind randomized phase II study of the combination of sorafenib and dacarbazine in patients with advanced melanoma: a report from the 11715 Study Group. J Clin Oncol 26:2178–2185

    Article  CAS  PubMed  Google Scholar 

  • McMahon N, Cheng TY, Beasley GM et al (2009) Optimizing melphalan pharmacokinetics in regional melanoma therapy: does correcting for ideal body weight alter regional response or toxicity? Ann Surg Oncol 16:953–961

    Article  CAS  PubMed  Google Scholar 

  • Mian R, Henderson MA, Speakman D et al (2001) Isolated limb infusion for melanoma: a simple alternative to isolated limb perfusion. Can J Surg 44:189–192

    CAS  PubMed  PubMed Central  Google Scholar 

  • Moreno-Ramirez D, de la Cruz-Merino L, Ferrandiz L et al (2010) Isolated limb perfusion for malignant melanoma: systematic review on effectiveness and safety. Oncologist 15:416–427

    Article  PubMed  PubMed Central  Google Scholar 

  • Muilenburg DJ, Beasley GM, Thompson ZJ et al (2015) Burden of disease predicts response to isolated limb infusion with melphalan and actinomycin D in melanoma. Ann Surg Oncol 22:482–488

    Article  PubMed  Google Scholar 

  • Mullinax JE, Kroon HM, Thompson JF et al (2017) Isolated limb infusion as a limb salvage strategy for locally advanced extremity sarcoma. J Am Coll Surg 224:635–642

    Article  PubMed  PubMed Central  Google Scholar 

  • Nieweg OE, Kroon BB (2014) Isolated limb perfusion with melphalan for melanoma. J Surg Oncol 109:332–337

    Article  PubMed  Google Scholar 

  • Noorda EM, Vrouenraets BC, Nieweg OE et al (2006) Repeat isolated limb perfusion with TNFalpha and melphalan for recurrent limb melanoma after failure of previous perfusion. Eur J Surg Oncol 32:318–324

    Article  CAS  PubMed  Google Scholar 

  • O’Donoghue C, Perez MC, Mullinax JE et al (2017) Isolated limb infusion: a single-center experience with over 200 infusions. Ann Surg Oncol 24:3842–3849

    Article  PubMed  PubMed Central  Google Scholar 

  • Parsons PG, Carter FB, Morrison L et al (1981) Mechanism of melphalan resistance developed in vitro in human melanoma cells. Cancer Res 41:1525–1534

    CAS  PubMed  Google Scholar 

  • Raigani S, Cohen S, Boland GM (2017) The role of surgery for melanoma in an era of effective systemic therapy. Curr Oncol Rep 19:17

    Article  PubMed  Google Scholar 

  • Raymond AK, Beasley GM, Broadwater G et al (2011) Current trends in regional therapy for melanoma: lessons learned from 225 regional chemotherapy treatments between 1995 and 2010 at a single institution. J Am Coll Surg 213:306–316

    Article  PubMed  PubMed Central  Google Scholar 

  • Roberts MS, Wu ZY, Siebert GA et al (2001a) Saturable dose-response relationships for melphalan in melanoma treatment by isolated limb infusion in the nude rat. Melanoma Res 11:611–618

    Article  CAS  PubMed  Google Scholar 

  • Roberts MS, Wu ZY, Siebert GA et al (2001b) Pharmacokinetics and pharmacodynamics of melphalan in isolated limb infusion for recurrent localized limb malignancy. Melanoma Res 11:423–431

    Article  CAS  PubMed  Google Scholar 

  • Sanki A, Kam PC, Thompson JF (2007) Long-term results of hyperthermic, isolated limb perfusion for melanoma: a reflection of tumor biology. Ann Surg 245:591–596

    Article  PubMed  PubMed Central  Google Scholar 

  • Santillan AA, Delman KA, Beasley GM et al (2009) Predictive factors of regional toxicity and serum creatine phosphokinase levels after isolated limb infusion for melanoma: a multi-institutional analysis. Ann Surg Oncol 16:2570–2578

    Article  PubMed  Google Scholar 

  • Scott RN, Blackie R, Kerr DJ et al (1990) Melphalan in isolated limb perfusion for malignant melanoma, bolus or divided dose, tissue levels, the pH effect. In: Jakesz R, Rainer H (eds) Progress in regional cancer therapy. Springer, Berlin/Heidelberg, pp 195–200

    Chapter  Google Scholar 

  • Siemann DW, Chapman M, Beikirch A (1991) Effects of oxygenation and pH on tumor cell response to alkylating chemotherapy. Int J Radiat Oncol Biol Phys 20:287–289

    Article  CAS  PubMed  Google Scholar 

  • Skarsgard LD, Skwarchuk MW, Vinczan A et al (1995) The cytotoxicity of melphalan and its relationship to pH, hypoxia and drug uptake. Anticancer Res 15: 219–223

    CAS  PubMed  Google Scholar 

  • Stehlin JS Jr (1969) Hyperthermic perfusion with chemotherapy for cancers of the extremities. Surg Gynecol Obstet 129:305–308

    PubMed  Google Scholar 

  • Thompson JF, Waugh RC, Saw RPM et al (1994a) Isolated limb infusion with melphalan for recurrent limb melanoma: a simple alternative to isolated limb perfusion. Reg Cancer Treat 7:188–192

    Google Scholar 

  • Thompson JF, Lai DT, Ingvar C et al (1994b) Maximizing efficacy and minimizing toxicity in isolated limb perfusion for melanoma. Melanoma Res 4(Suppl 1):45–50

    PubMed  Google Scholar 

  • Thompson JF, Siebert GA, Anissimov YG et al (2001) Microdialysis and response during regional chemotherapy by isolated limb infusion of melphalan for limb malignancies. Br J Cancer 85:157–165

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Thompson JF, Agarwala SS, Smithers BM et al (2015) Phase 2 study of intralesional PV-10 in refractory metastatic melanoma. Ann Surg Oncol 22:2135–2142

    Article  PubMed  Google Scholar 

  • Turaga KK, Beasley GM, Kane JM 3rd et al (2011) Limb preservation with isolated limb infusion for locally advanced nonmelanoma cutaneous and soft-tissue malignant neoplasms. Arch Surg 146:870–875

    Article  PubMed  PubMed Central  Google Scholar 

  • Ueno T, Ko SH, Grubbs E et al (2004) Temozolomide is a novel regional infusion agent for the treatment of advanced extremity melanoma. Am J Surg 188: 532–537

    Article  CAS  PubMed  Google Scholar 

  • Van der Merwe SA, Van den Berg AP, Kroon BB et al (1993) Modification of human tumour and normal tissue pH during hyperthermic and normothermic antiblastic regional isolation perfusion for malignant melanoma: a pilot study. Int J Hyperthermia 9:205–217

    Article  PubMed  Google Scholar 

  • Vrouenraets BC, Klaase JM, Nieweg OE et al (1998) Toxicity and morbidity of isolated limb perfusion. Semin Surg Oncol 14:224–231

    Article  CAS  PubMed  Google Scholar 

  • Weber J, Mandala M, Del Vecchio M et al (2017) Adjuvant nivolumab versus ipilimumab in resected stage III or IV melanoma. N Engl J Med 377:1824–1835

    Article  CAS  PubMed  Google Scholar 

  • Wieberdink J, Benckhuysen C, Braat RP et al (1982) Dosimetry in isolation perfusion of the limbs by assessment of perfused tissue volume and grading of toxic tissue reactions. Eur J Cancer Clin Oncol 18:905–910

    Article  CAS  PubMed  Google Scholar 

  • Wong J, Chen YA, Fisher KJ et al (2013) Isolated limb infusion in a series of over 100 infusions: a single-center experience. Ann Surg Oncol 20:1121–1127

    Article  PubMed  PubMed Central  Google Scholar 

  • Wong J, Chen YA, Fisher KJ et al (2014) Resection of residual disease after isolated limb infusion (ILI) is equivalent to a complete response after ILI-alone in advanced extremity melanoma. Ann Surg Oncol 21:650–655

    Article  PubMed  Google Scholar 

  • World Health Organization (1979) WHO handbook for reporting results of cancer treatments. WHO offset publication no. 48. World Health Organization, Geneva

    Google Scholar 

  • Wu ZY, Thompson MJ, Roberts MS et al (1995) High-performance liquid chromatographic assay for the measurement of melphalan and its hydrolysis products in perfusate and plasma and melphalan in tissues from human and rat isolated limb perfusions. J Chromatogr B Biomed Appl 673:267–279

    Article  CAS  PubMed  Google Scholar 

  • Wu ZY, Smithers BM, Anderson C et al (2000) Can tissue drug concentrations be monitored by microdialysis during or after isolated limb perfusion for melanoma treatment? Melanoma Res 10:47–54

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Surgery, Duke University Medical Center, Durham, NC, USA

    Georgia Marie Beasley & Douglas S. Tyler

  2. Department of Cutaneous Oncology, Moffitt Cancer Center, Tampa, FL, USA

    John T. Miura & Jonathan S. Zager

  3. Melanoma Institute Australia, The University of Sydney, Sydney, NSW, Australia

    Hidde M. Kroon

  4. Melanoma Institute Australia, Faculty of Medicine and Health,Central Clinical Schools, The University of Sydney, Sydney, NSW, Australia

    John F. Thompson

  5. Department of Melanoma and Surgical Oncology, Royal Prince Alfred Hospital, Sydney, NSW, Australia

    John F. Thompson

  6. Department of General Surgery, The University of Adelaide, Royal Adelaide Hospital, Adelaide, SA, Australia

    Hidde M. Kroon

  7. Department of Surgery, University of Texas Medical Branch, Galveston, TX, USA

    Douglas S. Tyler

Authors
  1. Georgia Marie Beasley
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. John T. Miura
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Jonathan S. Zager
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Douglas S. Tyler
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. John F. Thompson
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Hidde M. Kroon
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Hidde M. Kroon .

Editor information

Editors and Affiliations

  1. Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA

    Charles M. Balch

  2. Department of Oncology, Georgetown University Medical Center, Lombardi Comprehensive Cancer Center, Washington, DC, USA

    Michael B. Atkins

  3. Centre for Dermatooncology, Department of Dermatology, Eberhard Karls University, Tuebingen, Germany

    Claus Garbe

  4. Departments of Surgical Oncology and Cancer Biology, Melanoma and Skin Center, The University of Texas MD Anderson Cancer Center, Houston, TX, USA

    Jeffrey E. Gershenwald

  5. Dermatology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA

    Allan C. Halpern

  6. Departments of Medicine, Dermatology, and Translational Science, University of Pittsburgh and UPMC Hillman Cancer Center, Pittsburgh, PA, USA

    John M. Kirkwood

  7. Divisions of Cancer Medicine and Research, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia

    Grant A. McArthur

  8. Melanoma Institute Australia, Faculty of Medicine and Health, The University of Sydney, Sydney, NSW, Australia

    John F. Thompson

  9. Department of Dermatology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA

    Arthur J. Sober

Rights and permissions

Reprints and permissions

Copyright information

© 2020 Springer Nature Switzerland AG

About this entry

Check for updates. Verify currency and authenticity via CrossMark

Cite this entry

Beasley, G.M., Miura, J.T., Zager, J.S., Tyler, D.S., Thompson, J.F., Kroon, H.M. (2020). Isolated Limb Infusion for Melanoma. In: Balch, C., et al. Cutaneous Melanoma. Springer, Cham. https://doi.org/10.1007/978-3-030-05070-2_27

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-05070-2_27

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-030-05068-9

  • Online ISBN: 978-3-030-05070-2

  • eBook Packages: MedicineReference Module Medicine

Publish with us

Policies and ethics

Search

Navigation